Fate Therapeutics Inc (FATE)
Industry Biotechnology
This stock can be held in an Investment ISA and an Investment Account
Sell
$1.20
Buy
$1.23
$-0.02 (-1.61%)
Prices updated at 02 Apr 2026, 23:40 EDT
| Prices minimum 15 mins delay
Prices in USD
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of programmed cellular immunotherapies for cancer and immune disorders.
Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and
- Key stats
- Price
- Fair value
- Dividends
- News
- Financials
- Valuation
- Profile
Sector
Healthcare
Industry
Biotechnology
Chairman
Dr. William H. Rastetter,PhD
CEO
Dr. Bahram Valamehr, M.B.A.,PhD
Most recent earnings
31 Dec 2025
Fiscal year end
31 Dec 2025
Employees
161
Head office
12278 Scripps Summit Drive
San Diego
United States
92131
Key personnel
Owner name | Salary |
|---|---|
Dr. William H. Rastetter,PhD Chairman of the Board | 0.08m |
Dr. Robert S. Epstein, M.D.,M.S. Independent Director | 0.06m |
Mr. Matthew C. Abernethy Independent Director | - |
Dr. Shefali Agarwal, M.D.,M.P.H. Independent Director | 0.06m |
Mr. Michael Lee Independent Director | 0.05m |
Dr. Bahram Valamehr, M.B.A.,PhD Director, President and Chief Executive Officer | 0.53m |
Dr. Karin Jooss, PhD Independent Director | 0.06m |
Mr. Kamal Adawi, M.B.A.,M.S. Treasurer, Chief Financial Officer and Principal Accounting Officer | - |
Dr. Yuan Xu, PhD Independent Director | 0.05m |
Ms. Cindy R. Tahl, J.D. Chief Legal and Compliance Officer and Corporate Secretary | 0.50m |
Top 5 shareholders
Owner name | No. of shares |
|---|---|
| Redmile Group, LLC | 12,872,946 |
| BlackRock Inc | 10,680,727 |
| Vanguard Group Inc | 8,971,347 |
| Wilshire Advisors | 8,486,822 |
| BlackRock Fund Advisors | 3,915,865 |
Director dealings
Date | Action |
|---|---|
| 20 Oct 2025 | - |
| 20 Oct 2025 | - |
| 04 Aug 2025 | - |
| 04 Aug 2025 | - |
| 29 May 2025 | - |
| 29 May 2025 | - |
| 29 May 2025 | - |
| 29 May 2025 | - |
| 29 May 2025 | - |
| 29 May 2025 | - |
| 29 May 2025 | - |
| 29 May 2025 | - |
| 16 Jan 2025 | - |
| 15 Jan 2025 | - |
| 15 Jan 2025 | - |
| 15 Jan 2025 | - |
| 15 Jan 2025 | - |
| 10 Jan 2025 | - |
| 10 Jan 2025 | - |
| 10 Jan 2025 | - |
Please note that past performance is not a reliable indicator of future returns.